Jonathan Goldman

Jan 16, 2025 | villagevoice.com | Robert Shuster |Jonathan Goldman |Gideon Leek |R.C. Baker

“What made you write about the firestorm in Dresden?” a confused woman asked E. L. Doctorow during a 1986 Q&A with George Plimpton at the 92nd Street Y. She had Slaughterhouse-Five in mind.

Oct 9, 2024 | nature.com | Ferdinandos Skoulidis |Ana Cobo |Meagan Montesion |Yi Yu |Natalie I. Vokes |Joseph Murray | +44 more

AbstractFor patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB1,2.

Jul 3, 2024 | villagevoice.com | Jonathan Goldman |Shana Nys Dambrot

You can’t adapt James Joyce’s Ulysses for the stage, not the whole thing anyway. It’s too long, it’s too difficult, and it’s too plotless. Nothing really happens. Not enough people in the audience are likely to have actually read it and therefore be able to enjoy any Easter eggs, or delight in clever translations from page to stage. And really, Ulysses, serialized from 1918 to 1921 and published in one volume in 1922, is famously a novel of the interior life of its characters.

Jan 5, 2024 | espaciologopedico.com | Jonathan Goldman

Sonidos sanadores es el primer libro que expresa tanto el punto de vista científico como el espiritual sobre la utilización del poder transformador del sonido para curar física, emocional, mental y espiritualmente. Las escuelas de misterios de Egipto, Grecia y Roma sabían que la vibración es la fuerza activa fundamental del universo, y desarrollaron cantos y tonos específicos para curar la mente, el cuerpo y el espíritu, y para alcanzar estados alterados de consciencia.

Jul 21, 2023 | targetedonc.com | Jonathan Goldman

Jonathan W. Goldman, MD, associate professor of medicine in the hematology/oncology division, director of clinical trials in thoracic oncology, and the associate director of early drug development at UCLA Health, discusses the use of osimertinib (Tagrisso) in the first-line setting for patients with non–small cell lung cancer (NSCLC) whose disease harbors an EGFR mutation.